188 related articles for article (PubMed ID: 34837144)
1. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
6. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
7. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
9. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
[TBL] [Abstract][Full Text] [Related]
10. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
[TBL] [Abstract][Full Text] [Related]
11. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Panos NG; Cook AM; John S; Jones GM;
Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
[TBL] [Abstract][Full Text] [Related]
13. A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage.
Berger K; Santibañez M; Lin L; Lesch CA
J Intensive Care Med; 2020 Nov; 35(11):1203-1208. PubMed ID: 30983472
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
16. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
17. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants: Comparison with Warfarin.
Kawabori M; Niiya Y; Iwasaki M; Mabuchi S; Ozaki H; Matsubara K; Houkin K
J Stroke Cerebrovasc Dis; 2018 May; 27(5):1338-1342. PubMed ID: 29397310
[TBL] [Abstract][Full Text] [Related]
19. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
[TBL] [Abstract][Full Text] [Related]
20. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
